Moderna Targets 10% Growth, Diversifies Pipeline with T-Cell/CAR-T, CEO Optimistic on Flu Vaccine
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna forecasts up to 10% revenue growth for 2026, driven by new infectious disease vaccines and oncology/rare disease programs. The company also announced a significant strategic expansion into T-cell engagers and in-vivo CAR-T therapies at its Science Day, signaling a diversification into new, high-potential therapeutic modalities. This follows recent positive regulatory momentum for its mRNA-1010 flu vaccine, which received unanimous FDA advisory committee backing on June 18th, with the CEO expressing optimism for imminent clearance. The PDUFA date for the flu vaccine is August 5th.
At the time of this announcement, MRNA was trading at $59.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.7B. The 52-week trading range was $22.28 to $67.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.